
Sign up to save your podcasts
Or
Dr. DePas's lab is focused on developing a clear picture of the biogeography of infection sites, determining how the spatial structure impacts bacterial activity and interactions with host cells, and recapitulating important aspects of the infection environment in vitro in order to gain an in-depth understanding of cellular processes that are relevant to pathogenesis. To achieve these goals, they utilize MiPACT-HCR, a tissue-clearing and cellular visualization technique that allows for 3D imaging of fixed tissue samples, along with in vitro techniques to characterize the formation and dispersal of bacterial biofilms in conditions that mimic the in vivo environment. Dr. DePas's lab is chiefly interested in nontuberculous mycobacteria (NTM), emerging pathogens that are particularly problematic for patients with CF. By applying their described methodology, they are working to determine the context in which NTM form biofilms during infection and how biofilm formation contributes to disease severity.
4.8
4646 ratings
Dr. DePas's lab is focused on developing a clear picture of the biogeography of infection sites, determining how the spatial structure impacts bacterial activity and interactions with host cells, and recapitulating important aspects of the infection environment in vitro in order to gain an in-depth understanding of cellular processes that are relevant to pathogenesis. To achieve these goals, they utilize MiPACT-HCR, a tissue-clearing and cellular visualization technique that allows for 3D imaging of fixed tissue samples, along with in vitro techniques to characterize the formation and dispersal of bacterial biofilms in conditions that mimic the in vivo environment. Dr. DePas's lab is chiefly interested in nontuberculous mycobacteria (NTM), emerging pathogens that are particularly problematic for patients with CF. By applying their described methodology, they are working to determine the context in which NTM form biofilms during infection and how biofilm formation contributes to disease severity.
129 Listeners
2,045 Listeners
126 Listeners
313 Listeners
534 Listeners
482 Listeners
43,330 Listeners
279 Listeners
3,328 Listeners
111,102 Listeners
56,005 Listeners
87 Listeners
231 Listeners
314 Listeners
57,732 Listeners